The study, which is conducted in collaboration with the de Duve Institute, Brussels , is published in the Journal of Biological Chemistry and funded by the Medical Research Council, the Wellcome Trust, the Biotechnology and Biological Sciences Research Council and the European Commission. Professor Malcolm Walkinshaw, of the University of Edinburgh School of Biological Sciences , who participated in the research, said: ‘While this study a protein could linked sleeping sickness, the basic principle for all cells applies, including those in our bodies which helps.
This press release contains forward looking statements under the Private Securities Litigation Reform Act of 1995, the risks and uncertainties, known and unknown. Forward-looking statements reflect the current views and are based on certain assumptions and expectations are based. Such statements include statements with respect to these preliminary results, clinical development plans and prospects for Genaera programs including trodusquemine , the IL – 9 antibody program, LOMUCIN or squalamine. You can see some of these forward-looking statements by the use of words in the statements such as identifying ‘anticipate’, ‘believe’, ‘continue’, ‘develop ‘, ‘expect’, ‘plan’and ‘potential’or other words of similar meaning. Genaera ‘s actual results and performance may differ materially expressed from those currently anticipated and in these and other forward-looking statements as a result of a number of risk factors including, but not limited to: Genaera history of operating losses since inception and its need for additional funds for the operation of the company, the costs, Accompany delays and uncertainties in scientific research, drug development, clinical trials and the regulatory approval process, the risk that clinical trials for Genaera ‘s product candidates, including trodusquemine , the IL-9 antibody program, LOMUCIN or squalamine may be delayed or not be successful, the risk that Genaera may not obtain regulatory approval for its products, whether due to the adequacy of the development program, the conduct of the clinical trials, changing regulatory requirements, different methods of analysis and interpretation of data, regulatory interpretations of clinical risk and benefit, or not; Genaera confidence in his employees, in connection with the development and commercialization of Genaera product candidates, market acceptance reaches Genaera products if the authorization is granted, competition, general financial, economic, legal and political conditions, the biotechnology and pharmaceutical industries and other risks and uncertainties in this announcement and in Genaera filings with the U.S. Continue reading